Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ARG1 | P05089 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19846989 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MAPTRECQLGPR84HTR2A | |
| SCHEMBL14338216 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MAPTRECQLGPR84HTR2A | |
| 1-Methyltryptophan SCHEMBL14202956 | 0.88 | MAPT (0.71) | ALDH1A1MAPTRECQLGPR84HTR2A | |
| (L)-1-Methyltryptophan SCHEMBL19993 | 0.88 | MAPT (0.71) | ALDH1A1MAPTRECQLGPR84HTR2A | |
| SCHEMBL19231794 | 0.88 | SCN9A (0.57) | ALDH1A1MAPTRECQLGPR84HTR2A | |
| SCHEMBL24445574 | 0.88 | SCN9A (0.57) | ALDH1A1MAPTRECQLGPR84HTR2A | |
| Indoximod SCHEMBL29349777 | 0.88 | MAPT (0.71) | ALDH1A1MAPTRECQLGPR84HTR2A | |
| 1-Methyltryptophan SCHEMBL19992 | 0.88 | MAPT (0.71) | ALDH1A1MAPTRECQLGPR84HTR2A | |
| Indoximod SCHEMBL934800 | 0.88 | MAPT (0.71) | ALDH1A1MAPTRECQLGPR84HTR2A | |
| Indoximod SCHEMBL23668055 | 0.87 | MAPT (0.69) | ALDH1A1MAPTRECQLGPR84HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022035843-A1 | TOPOISOMERASE INHIBITORS | NANOMEDICINE INNOVATION CENTER, LLC (US) | 2022-02-17 | — | — | WO | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | ALDH1A1 4260/4885MAPT 2232/4885RECQL 2586/4885 |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | ALDH1A1 4260/4885MAPT 2232/4885RECQL 2586/4885 |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | ALDH1A1 4260/4885MAPT 2232/4885RECQL 2586/4885 |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | ALDH1A1 4260/4885MAPT 2232/4885RECQL 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.